Clinical practice recommendations for kidney involvement in tuberous sclerosis complex: a consensus statement by the ERKNet Working Group for Autosomal Dominant Structural Kidney Disorders and the ERA Genes & Kidney Working Group.
Journal
Nature reviews. Nephrology
ISSN: 1759-507X
Titre abrégé: Nat Rev Nephrol
Pays: England
ID NLM: 101500081
Informations de publication
Date de publication:
05 Mar 2024
05 Mar 2024
Historique:
accepted:
08
02
2024
medline:
6
3
2024
pubmed:
6
3
2024
entrez:
5
3
2024
Statut:
aheadofprint
Résumé
Tuberous sclerosis complex (TSC) is an autosomal dominant disorder characterized by the presence of proliferative lesions throughout the body. Management of TSC is challenging because patients have a multifaceted systemic illness with prominent neurological and developmental impact as well as potentially severe kidney, heart and lung phenotypes; however, every organ system can be involved. Adequate care for patients with TSC requires a coordinated effort involving a multidisciplinary team of clinicians and support staff. This clinical practice recommendation was developed by nephrologists, urologists, paediatric radiologists, interventional radiologists, geneticists, pathologists, and patient and family group representatives, with a focus on TSC-associated kidney manifestations. Careful monitoring of kidney function and assessment of kidney structural lesions by imaging enable early interventions that can preserve kidney function through targeted approaches. Here, we summarize the current evidence and present recommendations for the multidisciplinary management of kidney involvement in TSC.
Identifiants
pubmed: 38443710
doi: 10.1038/s41581-024-00818-0
pii: 10.1038/s41581-024-00818-0
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. Springer Nature Limited.
Références
Bissler, J. J. & Christopher Kingswood, J. Renal manifestation of tuberous sclerosis complex. Am. J. Med. Genet. C Semin. Med. Genet. 178, 338–347 (2018).
doi: 10.1002/ajmg.c.31654
Crino, P. B., Nathanson, K. L. & Henske, E. P. The tuberous sclerosis complex. N. Engl. J. Med. 355, 1345–1356 (2006).
doi: 10.1056/NEJMra055323
Yates, J. R. Tuberous sclerosis. Eur. J. Hum. Genet. 14, 1065–1073 (2006).
doi: 10.1038/sj.ejhg.5201625
Kingswood, J. C. et al. Renal angiomyolipoma in patients with tuberous sclerosis complex: findings from the TuberOus SClerosis registry to increase disease awareness. Nephrol. Dial. Transpl. 34, 502–508 (2019).
doi: 10.1093/ndt/gfy063
Zollner, J. P. et al. A systematic review on the burden of illness in individuals with tuberous sclerosis complex (TSC). Orphanet J. Rare Dis. 15, 23 (2020).
pmcid: 6975094
doi: 10.1186/s13023-019-1258-3
Bissler, J. J. & Kingswood, J. C. Optimal treatment of tuberous sclerosis complex associated renal angiomyolipomata: a systematic review. Ther. Adv. Urol. 8, 279–290 (2016).
pmcid: 5131738
doi: 10.1177/1756287216641353
Shepherd, C. W., Gomez, M. R., Lie, J. T. & Crowson, C. S. Causes of death in patients with tuberous sclerosis. Mayo Clin. Proc. 66, 792–796 (1991).
doi: 10.1016/S0025-6196(12)61196-3
Amin, S. et al. Causes of mortality in individuals with tuberous sclerosis complex. Dev. Med. Child Neurol. 59, 612–617 (2017).
doi: 10.1111/dmcn.13352
Ewalt, D. H., Sheffield, E., Sparagana, S. P., Delgado, M. R. & Roach, E. S. Renal lesion growth in children with tuberous sclerosis complex. J. Urol. 160, 141–145 (1998).
doi: 10.1016/S0022-5347(01)63072-6
Xu, Z., Wu, J., Xu, G. & Luo, H. Abdominal ultrasonographic manifestations in pediatric patients with tuberous sclerosis complex. Transl. Pediatr. 9, 757–767 (2020).
pmcid: 7804489
doi: 10.21037/tp-20-150
Ogorek, B. et al. TSC2 pathogenic variants are predictive of severe clinical manifestations in TSC infants: results of the EPISTOP study. Genet. Med. 22, 1489–1497 (2020).
doi: 10.1038/s41436-020-0823-4
Korula, S. et al. Renal manifestations of tuberous sclerosis among children: an Indian experience and review of the literature. Clin. Kidney J. 7, 134–137 (2014).
pmcid: 4377768
doi: 10.1093/ckj/sft162
Di Pinto, D., Balestracci, A. & Delgado, N. Renal manifestations of tuberous sclerosis in children [Spanish]. Arch. Argent. Pediatr. 107, 436–440 (2009).
Mettin, R. R. et al. Wide spectrum of clinical manifestations in children with tuberous sclerosis complex — follow-up of 20 children. Brain Dev. 36, 306–314 (2014).
doi: 10.1016/j.braindev.2013.05.006
Eijkemans, M. J. et al. Long-term follow-up assessing renal angiomyolipoma treatment patterns, morbidity, and mortality: an observational study in tuberous sclerosis complex patients in the Netherlands. Am. J. Kidney Dis. 66, 638–645 (2015).
doi: 10.1053/j.ajkd.2015.05.016
Kingswood, J. C. et al. Renal manifestations of tuberous sclerosis complex: key findings from the final analysis of the TOSCA study focussing mainly on renal angiomyolipomas. Front. Neurol. 11, 972 (2020).
pmcid: 7526256
doi: 10.3389/fneur.2020.00972
Warncke, J. C. et al. Pediatric renal angiomyolipomas in tuberous sclerosis complex. J. Urol. 197, 500–506 (2017).
doi: 10.1016/j.juro.2016.09.082
Northrup, H. et al. Updated International Tuberous Sclerosis Complex Diagnostic Criteria and Surveillance and Management Recommendations. Pediatr. Neurol. 123, 50–66 (2021).
doi: 10.1016/j.pediatrneurol.2021.07.011
Bissler, J. J. et al. Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis. N. Engl. J. Med. 358, 140–151 (2008).
pmcid: 3398441
doi: 10.1056/NEJMoa063564
Bissler, J. J. et al. Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet 381, 817–824 (2013).
doi: 10.1016/S0140-6736(12)61767-X
Bissler, J. J. et al. Tuberous sclerosis complex exhibits a new renal cystogenic mechanism. Physiol. Rep. 7, e13983 (2019).
pmcid: 6344348
doi: 10.14814/phy2.13983
Ouzzani, M., Hammady, H., Fedorowicz, Z. & Elmagarmid, A. Rayyan — a web and mobile app for systematic reviews. Syst. Rev. 5, 210 (2016).
pmcid: 5139140
doi: 10.1186/s13643-016-0384-4
American Academy of Pediatrics Steering Committee on Quality Improvement and Management. Classifying recommendations for clinical practice guidelines. Pediatrics 114, 874–877 (2004).
doi: 10.1542/peds.2004-1260
Salussolia, C. L., Klonowska, K., Kwiatkowski, D. J. & Sahin, M. Genetic etiologies, diagnosis, and treatment of tuberous sclerosis complex. Annu. Rev. Genomics Hum. Genet. 20, 217–240 (2019).
doi: 10.1146/annurev-genom-083118-015354
Richards, S. et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet. Med. 17, 405–424 (2015).
pmcid: 4544753
doi: 10.1038/gim.2015.30
Giannikou, K. et al. Low-level mosaicism in tuberous sclerosis complex: prevalence, clinical features, and risk of disease transmission. Genet. Med. 21, 2639–2643 (2019).
doi: 10.1038/s41436-019-0562-6
Tyburczy, M. E. et al. Mosaic and intronic mutations in TSC1/TSC2 explain the majority of TSC patients with no mutation identified by conventional testing. PLoS Genet. 11, e1005637 (2015).
pmcid: 4634999
doi: 10.1371/journal.pgen.1005637
Treichel, A. M. et al. Phenotypic distinctions between mosaic forms of tuberous sclerosis complex. Genet. Med. 21, 2594–2604 (2019).
pmcid: 7875483
doi: 10.1038/s41436-019-0520-3
Klonowska, K. et al. Comprehensive genetic and phenotype analysis of 95 individuals with mosaic tuberous sclerosis complex. Am. J. Hum. Genet. 110, 979–988 (2023).
pmcid: 10257004
doi: 10.1016/j.ajhg.2023.04.002
Devuyst, O. & Pei, Y. Next-generation sequencing for detection of somatic mosaicism in autosomal dominant polycystic kidney disease. Kidney Int. 97, 261–263 (2020).
doi: 10.1016/j.kint.2019.11.019
Treichel, A. M., Kwiatkowski, D. J., Moss, J. & Darling, T. N. A diagnostic algorithm for enhanced detection of mosaic tuberous sclerosis complex in adults. Br. J. Dermatol. 182, 235–237 (2020).
Kozlowski, P. et al. Identification of 54 large deletions/duplications in TSC1 and TSC2 using MLPA, and genotype-phenotype correlations. Hum. Genet. 121, 389–400 (2007).
doi: 10.1007/s00439-006-0308-9
Sampson, J. R. et al. Renal cystic disease in tuberous sclerosis: role of the polycystic kidney disease 1 gene. Am. J. Hum. Genet. 61, 843–851 (1997).
pmcid: 1716004
doi: 10.1086/514888
Lyczkowski, D. A. et al. Intrafamilial phenotypic variability in tuberous sclerosis complex. J. Child Neurol. 22, 1348–1355 (2007).
doi: 10.1177/0883073807307093
Northrup, H., et al. (University of Washington, Seattle Copyright © 1993-2023, University of Washington, Seattle. GeneReviews is a registered trademark of the University of Washington, Seattle. All rights reserved., 1993).
Jones, A. C. et al. Comprehensive mutation analysis of TSC1 and TSC2-and phenotypic correlations in 150 families with tuberous sclerosis. Am. J. Hum. Genet. 64, 1305–1315 (1999).
pmcid: 1377866
doi: 10.1086/302381
Au, K. S. et al. Genotype/phenotype correlation in 325 individuals referred for a diagnosis of tuberous sclerosis complex in the United States. Genet. Med. 9, 88–100 (2007).
doi: 10.1097/GIM.0b013e31803068c7
Dabora, S. L. et al. Mutational analysis in a cohort of 224 tuberous sclerosis patients indicates increased severity of TSC2, compared with TSC1, disease in multiple organs. Am. J. Hum. Genet. 68, 64–80 (2001).
doi: 10.1086/316951
Sancak, O. et al. Mutational analysis of the TSC1 and TSC2 genes in a diagnostic setting: genotype — phenotype correlations and comparison of diagnostic DNA techniques in tuberous sclerosis complex. Eur. J. Hum. Genet. 13, 731–741 (2005).
doi: 10.1038/sj.ejhg.5201402
Kothare, S. V. et al. Severity of manifestations in tuberous sclerosis complex in relation to genotype. Epilepsia 55, 1025–1029 (2014).
doi: 10.1111/epi.12680
Kothare, S. V. et al. Genotype/phenotype in tuberous sclerosis complex: associations with clinical and radiologic manifestations. Epilepsia 55, 1020–1024 (2014).
doi: 10.1111/epi.12627
Avgeris, S. et al. Mutational analysis of TSC1 and TSC2 genes in tuberous sclerosis complex patients from greece. Sci. Rep. 7, 16697 (2017).
pmcid: 5711901
doi: 10.1038/s41598-017-16988-w
Bai, D., Zhao, J., Li, L., Gao, J. & Wang, X. Analysis of genotypes and phenotypes in Chinese children with tuberous sclerosis complex. Sci. China Life Sci. 60, 763–771 (2017).
doi: 10.1007/s11427-017-9091-x
Cai, Y., Li, H. & Zhang, Y. Assessment of tuberous sclerosis complex associated with renal lesions by targeted next-generation sequencing in mainland China. Urology 101, 170.e1–170.e7 (2017).
doi: 10.1016/j.urology.2016.10.056
Lin, S. et al. Tuberous sclerosis complex in Chinese patients: phenotypic analysis and mutational screening of TSC1/TSC2 genes. Seizure 71, 322–327 (2019).
doi: 10.1016/j.seizure.2019.08.010
Ding, Y. et al. Genotype and phenotype analysis of Chinese children with tuberous sclerosis complex: a pediatric cohort study. Front. Genet. 11, 204 (2020).
pmcid: 7076134
doi: 10.3389/fgene.2020.00204
Yang, G. et al. Phenotypic and genotypic characterization of Chinese children diagnosed with tuberous sclerosis complex. Clin. Genet. 91, 764–768 (2017).
doi: 10.1111/cge.12920
Togi, S., Ura, H., Hatanaka, H. & Niida, Y. Genotype and phenotype landscape of 283 Japanese patients with tuberous sclerosis complex. Int. J. Mol. Sci. 23, 11175 (2022).
pmcid: 9569560
doi: 10.3390/ijms231911175
Rosset, C. et al. Molecular analysis of TSC1 and TSC2 genes and phenotypic correlations in Brazilian families with tuberous sclerosis. PLoS One 12, e0185713 (2017).
pmcid: 5624610
doi: 10.1371/journal.pone.0185713
Alsowat, D. et al. The phenotypic spectrum of tuberous sclerosis complex: a Canadian cohort. Child Neurol. Open 8, 2329048x211012817 (2021).
pmcid: 8114745
doi: 10.1177/2329048X211012817
Hung, C. C. et al. Molecular and clinical analyses of 84 patients with tuberous sclerosis complex. BMC Med. Genet. 7, 72 (2006).
pmcid: 1592085
doi: 10.1186/1471-2350-7-72
Farach, L. S. et al. Tuberous sclerosis complex genotypes and developmental phenotype. Pediatr. Neurol. 96, 58–63 (2019).
pmcid: 6837240
doi: 10.1016/j.pediatrneurol.2019.03.003
Farach, L. S. et al. TSC2 c.1864C>T variant associated with mild cases of tuberous sclerosis complex. Am. J. Med. Genet. A 173, 771–775 (2017).
doi: 10.1002/ajmg.a.38083
Khare, L. et al. A novel missense mutation in the GTPase activating protein homology region of TSC2 in two large families with tuberous sclerosis complex. J. Med. Genet. 38, 347–349 (2001).
pmcid: 1734876
doi: 10.1136/jmg.38.5.347
Jansen, A. C. et al. Unusually mild tuberous sclerosis phenotype is associated with TSC2 R905Q mutation. Ann. Neurol. 60, 528–539 (2006).
doi: 10.1002/ana.21037
Hulshof, H. M. et al. Counselling in tuberous sclerosis complex: a survey on content and satisfaction in the Netherlands. Eur. J. Paediatr. Neurol. 25, 113–119 (2020).
doi: 10.1016/j.ejpn.2020.01.004
Yang, X. Y. et al. Noninvasive prenatal diagnosis based on cell-free DNA for tuberous sclerosis: a pilot study. Mol. Genet. Genom. Med. 10, e1952 (2022).
doi: 10.1002/mgg3.1952
Wang, X. et al. Prenatal diagnosis and intervention improve developmental outcomes and epilepsy prognosis in children with tuberous sclerosis complex. Dev. Med. Child Neurol. 64, 1230–1236 (2022).
doi: 10.1111/dmcn.15265
Kotulska, K. et al. Prevention of epilepsy in infants with tuberous sclerosis complex in the EPISTOP trial. Ann. Neurol. 89, 304–314 (2021).
doi: 10.1002/ana.25956
Janssens, P. et al. Renal progression factors in young patients with tuberous sclerosis complex: a retrospective cohort study. Pediatr. Nephrol. 33, 2085–2093 (2018).
doi: 10.1007/s00467-018-4003-6
Vabret, E., Couchoud, C., Lassalle, M. & Vigneau, C. From tuberous sclerosis complex to end stage renal disease: who are these patients? J. Nephrol. 34, 607–615 (2021).
doi: 10.1007/s40620-020-00714-3
Ruggenenti, P., Perna, A. & Remuzzi, G. ACE inhibitors to prevent end-stage renal disease: when to start and why possibly never to stop: a post hoc analysis of the REIN trial results. Ramipril Efficacy in Nephropathy. J. Am. Soc. Nephrol. 12, 2832–2837 (2001).
doi: 10.1681/ASN.V12122832
Duerr, M. et al. Increased incidence of angioedema with ACE inhibitors in combination with mTOR inhibitors in kidney transplant recipients. Clin. J. Am. Soc. Nephrol. 5, 703–708 (2010).
pmcid: 2849684
doi: 10.2215/CJN.07371009
Cheung, A. K. et al. Executive summary of the KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease. Kidney Int. 99, 559–569 (2021).
doi: 10.1016/j.kint.2020.10.026
Williams, B. et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur. Heart J. 39, 3021–3104 (2018).
doi: 10.1093/eurheartj/ehy339
Lurbe, E. et al. 2016 European Society of Hypertension guidelines for the management of high blood pressure in children and adolescents. J. Hypertens. 34, 1887–1920 (2016).
doi: 10.1097/HJH.0000000000001039
Flynn, J. T. et al. Clinical practice guideline for screening and management of high blood pressure in children and adolescents. Pediatrics 140, e20171904 (2017).
doi: 10.1542/peds.2017-1904
Schrier, R. W. ACE inhibitors, left ventricular mass and renal cyst growth in ADPKD. Pharmacol. Res. 114, 166–168 (2016).
doi: 10.1016/j.phrs.2016.10.002
Bissler, J. et al. Long-term clinical morbidity in patients with renal angiomyolipoma associated with tuberous sclerosis complex. Urology 95, 80–87 (2016).
doi: 10.1016/j.urology.2016.04.027
Vekeman, F. et al. Kidney involvement in tuberous sclerosis complex: the impact on healthcare resource use and costs. J. Med. Econ. 18, 1060–1070 (2015).
doi: 10.3111/13696998.2015.1075995
Malaga-Dieguez, L. et al. Early manifestations of renal disease in patients with tuberous sclerosis complex. Int. J. Nephrol. Renovasc. Dis. 10, 91–95 (2017).
pmcid: 5422499
doi: 10.2147/IJNRD.S123638
Schwartz, G. J. et al. New equations to estimate GFR in children with CKD. J. Am. Soc. Nephrol. 20, 629–637 (2009).
pmcid: 2653687
doi: 10.1681/ASN.2008030287
Reese, P. P. & Feldman, H. I. More evidence that cystatin C predicts mortality better than creatinine. J. Am. Soc. Nephrol. 20, 2088–2090 (2009).
doi: 10.1681/ASN.2009080832
Stevens, P. E. & Levin, A. Evaluation and management of chronic kidney disease: synopsis of the kidney disease: improving global outcomes 2012 clinical practice guideline. Ann. Intern. Med. 158, 825–830 (2013).
doi: 10.7326/0003-4819-158-11-201306040-00007
Anis, O. et al. Selective arterial embolization for large or symptomatic renal angiomyolipoma: 10 years of follow-up. Urology 135, 82–87 (2020).
doi: 10.1016/j.urology.2019.09.035
Lin, L. et al. Renal function, complications, and outcomes of a reduction in tumor size after transarterial embolization for renal angiomyolipomas: a meta-analysis. J. Int. Med. Res. 47, 1417–1428 (2019).
pmcid: 6460598
doi: 10.1177/0300060519834447
Kronick, J., Gabril, M. Y. & House, A. A. Microscopic kidney disease in tuberous sclerosis complex and treatment with mTOR inhibition. Am. J. Kidney Dis. 82, 772–775 (2023).
doi: 10.1053/j.ajkd.2023.04.016
Bissler, J. J., Batchelor, D. & Kingswood, J. C. Progress in tuberous sclerosis complex renal disease. Crit. Rev. Oncog. 27, 35–49 (2022).
doi: 10.1615/CritRevOncog.2022042857
Bissler, J. J. et al. Effect of everolimus on renal function in patients with tuberous sclerosis complex: evidence from EXIST-1 and EXIST-2. Nephrol. Dial. Transpl. 34, 1000–1008 (2019).
doi: 10.1093/ndt/gfy132
Sharma, S. & Smyth, B. From proteinuria to fibrosis: an update on pathophysiology and treatment options. Kidney Blood Press. Res. 46, 411–420 (2021).
doi: 10.1159/000516911
Ho, T. A. et al. Autosomal dominant polycystic kidney disease is associated with central and nephrogenic defects in osmoregulation. Kidney Int. 82, 1121–1129 (2012).
doi: 10.1038/ki.2012.225
Janssens, P. et al. Expanding the role of vasopressin antagonism in polycystic kidney diseases: from adults to children? Pediatr. Nephrol. 33, 395–408 (2018).
doi: 10.1007/s00467-017-3672-x
Chapman, A. B. et al. Autosomal-dominant polycystic kidney disease (ADPKD): executive summary from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney Int. 88, 17–27 (2015).
pmcid: 4913350
doi: 10.1038/ki.2015.59
Suwabe, T. et al. Clinical features of cyst infection and hemorrhage in ADPKD: new diagnostic criteria. Clin. Exp. Nephrol. 16, 892–902 (2012).
doi: 10.1007/s10157-012-0650-2
Jouret, F., Hogan, M. C. & Chebib, F. T. A practical guide for the management of acute abdominal pain with fever in patients with autosomal dominant polycystic kidney disease. Nephrol. Dial. Transpl. 37, 1426–1428 (2022).
doi: 10.1093/ndt/gfab040
Acharya, P. et al. Incidence and characteristics of kidney stones in patients on ketogenic diet: a systematic review and meta-analysis. Diseases 9, 39 (2021).
pmcid: 8161846
doi: 10.3390/diseases9020039
Reyna-Fabián, M. E. et al. TSC2/PKD1 contiguous gene syndrome, with emphasis on a case with an atypical mild polycystic kidney phenotype and a novel genetic variant. Nefrologia 40, 91–98 (2020).
doi: 10.1016/j.nefro.2019.03.003
Griffin, M. D. et al. Neonatal presentation of autosomal dominant polycystic kidney disease with a maternal history of tuberous sclerosis. Nephrol. Dial. Transpl. 12, 2284–2288 (1997).
doi: 10.1093/ndt/12.11.2284
Northrup, H., Krueger, D. A. & International Tuberous Sclerosis Complex Consensus Group. Tuberous sclerosis complex diagnostic criteria update: recommendations of the 2012 international tuberous sclerosis complex consensus conference. Pediatr. Neurol. 49, 243–254 (2013).
pmcid: 4080684
doi: 10.1016/j.pediatrneurol.2013.08.001
Patel, U., Simpson, E., Kingswood, J. C. & Saggar-Malik, A. K. Tuberose sclerosis complex: analysis of growth rates aids differentiation of renal cell carcinoma from atypical or minimal-fat-containing angiomyolipoma. Clin. Radiol. 60, 665–673 (2005).
doi: 10.1016/j.crad.2005.01.009
Avila, N. A., Dwyer, A. J. & Moss, J. Active surveillance of nonfatty renal masses in patients with lymphangioleiomyomatosis: use of CT features and patterns of growth to differentiate angiomyolipoma from renal cancer. AJR Am. J. Roentgenol. 209, 611–619 (2017).
pmcid: 8690630
doi: 10.2214/AJR.16.17530
Lane, B. R. et al. Clinical correlates of renal angiomyolipoma subtypes in 209 patients: classic, fat poor, tuberous sclerosis associated and epithelioid. J. Urol. 180, 836–843 (2008).
doi: 10.1016/j.juro.2008.05.041
Rabenou, R. A. & Charles, H. W. Differentiation of sporadic versus tuberous sclerosis complex-associated angiomyolipoma. AJR Am. J. Roentgenol. 205, 292–301 (2015).
doi: 10.2214/AJR.14.14255
Dixon, B. P., Hulbert, J. C. & Bissler, J. J. Tuberous sclerosis complex renal disease. Nephron 118, e15–e20 (2011).
Koo, K. C. et al. Trends of presentation and clinical outcome of treated renal angiomyolipoma. Yonsei Med. J. 51, 728–734 (2010).
pmcid: 2908871
doi: 10.3349/ymj.2010.51.5.728
Rouviere, O., Nivet, H., Grenier, N., Zini, L. & Lechevallier, E. Kidney damage due to tuberous sclerosis complex: management recommendations. Diagn. Interv. Imaging 94, 225–237 (2013).
doi: 10.1016/j.diii.2013.01.003
Buj Pradilla, M. J., Marti Balleste, T., Torra, R. & Villacampa Auba, F. Recommendations for imaging-based diagnosis and management of renal angiomyolipoma associated with tuberous sclerosis complex. Clin. Kidney J. 10, 728–737 (2017).
pmcid: 5716090
doi: 10.1093/ckj/sfx094
Jinzaki, M., Silverman, S. G., Akita, H., Mikami, S. & Oya, M. Diagnosis of renal angiomyolipomas: classic, fat-poor, and epithelioid types. Semin. Ultrasound CT MR 38, 37–46 (2017).
doi: 10.1053/j.sult.2016.11.001
Chan, J. P. et al. Utility of contrast-enhanced ultrasound for solid mass surveillance and characterization in children with tuberous sclerosis complex: an initial experience. Pediatr. Nephrol. 36, 1775–1784 (2021).
doi: 10.1007/s00467-020-04835-6
Champagnac, J. et al. Microaneurysms in renal angiomyolipomas: can clinical and computed tomography features predict their presence and size? Diagn. Interv. Imaging 97, 321–326 (2016).
doi: 10.1016/j.diii.2015.12.004
Heller, M. T., Furlan, A. & Kawashima, A. Multiparametric MR for solid renal mass characterization. Magn. Reson. Imaging Clin. N. Am. 28, 457–469 (2020).
doi: 10.1016/j.mric.2020.03.008
Schieda, N. et al. Multicenter evaluation of multiparametric MRI clear cell likelihood scores in solid indeterminate small renal masses. Radiology 303, 590–599 (2022).
doi: 10.1148/radiol.211680
Dickinson, M., Ruckle, H., Beaghler, M. & Hadley, H. R. Renal angiomyolipoma: optimal treatment based on size and symptoms. Clin. Nephrol. 49, 281–286 (1998).
Sward, J., Henrikson, O., Lyrdal, D., Peeker, R. & Lundstam, S. Renal angiomyolipoma-patient characteristics and treatment with focus on active surveillance. Scand. J. Urol. 54, 141–146 (2020).
doi: 10.1080/21681805.2020.1716066
Kuusk, T. et al. Treatment of renal angiomyolipoma: pooled analysis of individual patient data. BMC Urol. 15, 123 (2015).
pmcid: 4693425
doi: 10.1186/s12894-015-0118-2
Lee, K. H. et al. Clinical behavior and management of three types of renal angiomyolipomas. J. Formos. Med. Assoc. 118, 162–169 (2019).
doi: 10.1016/j.jfma.2018.02.012
Krueger, D. A., Northrup, H. & International Tuberous Sclerosis Complex Consensus Group. Tuberous sclerosis complex surveillance and management: recommendations of the 2012 International Tuberous Sclerosis Complex Consensus Conference. Pediatr. Neurol. 49, 255–265 (2013).
pmcid: 4058297
doi: 10.1016/j.pediatrneurol.2013.08.002
Ruud Bosch, J. L. H. et al. Factors associated with the number and size of renal angiomyolipomas in sporadic angiomyolipoma (sAML): a study of adult patients with sAML managed in a Dutch tertiary referral center. Int. Urol. Nephrol. 50, 459–467 (2018).
pmcid: 5845070
doi: 10.1007/s11255-017-1766-9
Nelson, C. P. & Sanda, M. G. Contemporary diagnosis and management of renal angiomyolipoma. J. Urol. 168, 1315–1325 (2002).
doi: 10.1016/S0022-5347(05)64440-0
Xu, X. F. et al. A scoring system based on clinical features for the prediction of sporadic renal angiomyolipoma rupture and hemorrhage. Medicine 99, e20167 (2020).
pmcid: 7254028
doi: 10.1097/MD.0000000000020167
Dabbeche, C. et al. Role of embolization in renal angiomyolipomas [French]. J. Radiol. 87, 1859–1867 (2006).
doi: 10.1016/S0221-0363(06)74166-X
Zeid, M. et al. Active surveillance for renal angiomyolipoma less than 4 centimeters: a systematic review of cohort studies. Cureus 14, e22678 (2022).
pmcid: 8966366
Cockerell, I. et al. Prevalence of renal angiomyolipomas and spontaneous bleeding related to angiomyolipomas in tuberous sclerosis complex patients in France and Norway — a questionnaire study. Urology 104, 70–76 (2017).
doi: 10.1016/j.urology.2017.02.023
Bhatt, J. R. et al. Natural history of renal angiomyolipoma (AML): most patients with large AMLs >4cm can be offered active surveillance as an initial management strategy. Eur. Urol. 70, 85–90 (2016).
doi: 10.1016/j.eururo.2016.01.048
Ouzaid, I. et al. Active surveillance for renal angiomyolipoma: outcomes and factors predictive of delayed intervention. BJU Int. 114, 412–417 (2014).
doi: 10.1111/bju.12604
Yamakado, K. et al. Renal angiomyolipoma: relationships between tumor size, aneurysm formation, and rupture. Radiology 225, 78–82 (2002).
doi: 10.1148/radiol.2251011477
Rimon, U. et al. Large renal angiomyolipomas: digital subtraction angiographic grading and presentation with bleeding. Clin. Radiol. 61, 520–526 (2006).
doi: 10.1016/j.crad.2006.02.003
Cockerell, I. et al. Renal manifestations of tuberous sclerosis complex: patients’ and parents’ knowledge and routines for renal follow-up — a questionnaire study. BMC Nephrol. 19, 39 (2018).
pmcid: 5812037
doi: 10.1186/s12882-018-0835-3
Goedken, A. M., Samuels, J. A., Sato, T. S. & Harshman, L. A. Kidney imaging surveillance in commercially insured patients with tuberous sclerosis complex. Pediatr. Neurol. 117, 21–26 (2021).
doi: 10.1016/j.pediatrneurol.2020.12.008
Tsai, J. D., Wei, C. C., Chen, S. M., Lue, K. H. & Sheu, J. N. Association between the growth rate of renal cysts/angiomyolipomas and age in the patients with tuberous sclerosis complex. Int. Urol. Nephrol. 46, 1685–1690 (2014).
doi: 10.1007/s11255-014-0701-6
Rakowski, S. K. et al. Renal manifestations of tuberous sclerosis complex: incidence, prognosis, and predictive factors. Kidney Int. 70, 1777–1782 (2006).
doi: 10.1038/sj.ki.5001853
Robert, A. et al. Renal involvement in tuberous sclerosis complex with emphasis on cystic lesions. Radiol. Med. 121, 402–408 (2016).
doi: 10.1007/s11547-015-0572-7
Lendvay, T. S., Broecker, B. & Smith, E. A. Renal cell carcinoma in a 2-year-old child with tuberous sclerosis. J. Urol. 168, 1131–1132 (2002).
doi: 10.1016/S0022-5347(05)64608-3
Allison, J. W., James, C. A. & Figarola, M. S. Pediatric case of the day. Renal cell carcinoma in a child with tuberous sclerosis. Radiographics 19, 1388–1389 (1999).
doi: 10.1148/radiographics.19.5.g99se231388
Al-Saleem, T. et al. Malignant tumors of the kidney, brain, and soft tissues in children and young adults with the tuberous sclerosis complex. Cancer 83, 2208–2216 (1998).
doi: 10.1002/(SICI)1097-0142(19981115)83:10<2208::AID-CNCR21>3.0.CO;2-K
Guo, J. et al. Tuberous sclerosis-associated renal cell carcinoma: a clinicopathologic study of 57 separate carcinomas in 18 patients. Am. J. Surg. Pathol. 38, 1457–1467 (2014).
doi: 10.1097/PAS.0000000000000248
Breysem, L., Nijs, E., Proesmans, W. & Smet, M. H. Tuberous sclerosis with cystic renal disease and multifocal renal cell carcinoma in a baby girl. Pediatr. Radiol. 32, 677–680 (2002).
doi: 10.1007/s00247-002-0765-9
Peron, A. et al. Do patients with tuberous sclerosis complex have an increased risk for malignancies? Am. J. Med. Genet. A 170, 1538–1544 (2016).
doi: 10.1002/ajmg.a.37644
Henske, E. P., Cornejo, K. M. & Wu, C. L. Renal cell carcinoma in tuberous sclerosis complex. Genes 12, 1585 (2021).
pmcid: 8535193
doi: 10.3390/genes12101585
Yang, P. et al. Renal cell carcinoma in tuberous sclerosis complex. Am. J. Surg. Pathol. 38, 895–909 (2014).
pmcid: 4139167
doi: 10.1097/PAS.0000000000000237
Tyburczy, M. E. et al. A shower of second hit events as the cause of multifocal renal cell carcinoma in tuberous sclerosis complex. Hum. Mol. Genet. 24, 1836–1842 (2015).
doi: 10.1093/hmg/ddu597
Sauter, M. et al. Rare manifestations and malignancies in tuberous sclerosis complex: findings from the TuberOus SClerosis registry to increAse disease awareness (TOSCA). Orphanet J. Rare Dis. 16, 301 (2021).
pmcid: 8259106
doi: 10.1186/s13023-021-01917-y
Yeoh, Z. W. et al. Natural history of angiomyolipoma in lymphangioleiomyomatosis: implications for screening and surveillance. Orphanet J. Rare Dis. 9, 151 (2014).
pmcid: 4203902
doi: 10.1186/s13023-014-0151-3
Battelli, C. & Cho, D. C. mTOR inhibitors in renal cell carcinoma. Therapy 8, 359–367 (2011).
pmcid: 3164983
doi: 10.2217/thy.11.32
Sasongko, T. H., Ismail, N. F. & Zabidi-Hussin, Z. Rapamycin and rapalogs for tuberous sclerosis complex. Cochrane Database Syst. Rev. 7, Cd011272 (2016).
Swallow, E. et al. Patterns of disease monitoring and treatment among patients with tuberous sclerosis complex-related angiomyolipomas. Urology 104, 110–114 (2017).
doi: 10.1016/j.urology.2017.02.036
Bissler, J. J. et al. Everolimus for renal angiomyolipoma in patients with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis: extension of a randomized controlled trial. Nephrol. Dial. Transpl. 31, 111–119 (2016).
doi: 10.1093/ndt/gfv249
Siroky, B. J. et al. Improvement in renal cystic disease of tuberous sclerosis complex after treatment with mammalian target of rapamycin inhibitor. J. Pediatr. 187, 318–322.e2 (2017).
doi: 10.1016/j.jpeds.2017.05.015
Kingswood, J. C. et al. The effect of everolimus on renal angiomyolipoma in patients with tuberous sclerosis complex being treated for subependymal giant cell astrocytoma: subgroup results from the randomized, placebo-controlled, phase 3 trial EXIST-1. Nephrol. Dial. Transpl. 29, 1203–1210 (2014).
doi: 10.1093/ndt/gfu013
Watanabe, E. H. et al. The effect of sirolimus on angiomyolipoma is determined by decrease of fat-poor compartments and includes striking reduction of vascular structures. Sci. Rep. 11, 8493 (2021).
pmcid: 8055687
doi: 10.1038/s41598-021-87930-4
Wang, W. et al. CT characteristics predict the response to everolimus or sirolimus of renal angiomyolipomas in patients with tuberous sclerosis complex. Int. Urol. Nephrol. 51, 671–676 (2019).
doi: 10.1007/s11255-019-02093-6
Hatano, T. et al. Effect of everolimus treatment for regrown renal angiomyolipoma associated with tuberous sclerosis complex after transcatheter arterial embolization. Int. J. Clin. Oncol. 23, 1134–1139 (2018).
doi: 10.1007/s10147-018-1325-0
Brakemeier, S. et al. Treatment effect of mTOR-inhibition on tissue composition of renal angiomyolipomas in tuberous sclerosis complex (TSC). PLoS One 12, e0189132 (2017).
pmcid: 5726644
doi: 10.1371/journal.pone.0189132
Zonnenberg, B. A. et al. Observational study of characteristics and clinical outcomes of Dutch patients with tuberous sclerosis complex and renal angiomyolipoma treated with everolimus. PLoS One 13, e0204646 (2018).
pmcid: 6237294
doi: 10.1371/journal.pone.0204646
Bissler, J. J. et al. Effect of everolimus on renal function in patients with tuberous sclerosis complex (TSC): results from exist-1 and exist-2. Nephrol. Dial. Transplant. 29, iii43–iii44 (2014).
Budde, K. et al. Pharmacokinetics and pharmacodynamics of everolimus in patients with renal angiomyolipoma and tuberous sclerosis complex or lymphangioleiomyomatosis. Br. J. Clin. Pharmacol. 81, 958–970 (2016).
pmcid: 4834586
doi: 10.1111/bcp.12834
Bissler, J. J. et al. The effect of everolimus on renal angiomyolipoma in pediatric patients with tuberous sclerosis being treated for subependymal giant cell astrocytoma. Pediatr. Nephrol. 33, 101–109 (2018).
doi: 10.1007/s00467-017-3806-1
Hatano, T., Chikaraishi, K., Inaba, H., Endo, K. & Egawa, S. Outcomes of everolimus treatment for renal angiomyolipoma associated with tuberous sclerosis complex: a single institution experience in Japan. Int. J. Urol. 23, 833–838 (2016).
doi: 10.1111/iju.13168
Robles, N. R. et al. Everolimus safety and efficacy for renal angiomyolipomas associated with tuberous sclerosis complex: a Spanish expanded access trial. Orphanet J. Rare Dis. 11, 128 (2016).
pmcid: 5037621
doi: 10.1186/s13023-016-0517-9
Cai, Y. et al. Assessing the outcomes of everolimus on renal angiomyolipoma associated with tuberous sclerosis complex in China: a two years trial. Orphanet J. Rare Dis. 13, 43 (2018).
pmcid: 5870799
doi: 10.1186/s13023-018-0781-y
Wu, C. Q., Wolf, D. S. & Smith, E. A. Fate of pediatric renal angiomyolipoma during mTOR inhibitor treatment in tuberous sclerosis complex. Urology 139, 161–167 (2020).
doi: 10.1016/j.urology.2019.12.041
Hatano, T., Endo, K. & Tamari, M. Efficacy and safety of low-dose everolimus treatment for renal angiomyolipoma associated with tuberous sclerosis complex. Int. J. Clin. Oncol. 26, 163–168 (2021).
doi: 10.1007/s10147-020-01792-w
Hatano, T., Inaba, H., Endo, K. & Egawa, S. Intermittent everolimus administration for renal angiomyolipoma associated with tuberous sclerosis complex. Int. J. Urol. 24, 780–785 (2017).
doi: 10.1111/iju.13428
Cabrera-López, C. et al. Assessing the effectiveness of rapamycin on angiomyolipoma in tuberous sclerosis: a two years trial. Orphanet J. Rare Dis. 7, 87 (2012).
pmcid: 3519505
doi: 10.1186/1750-1172-7-87
Davies, D. M. et al. Sirolimus therapy for angiomyolipoma in tuberous sclerosis and sporadic lymphangioleiomyomatosis: a phase 2 trial. Clin. Cancer Res. 17, 4071–4081 (2011).
doi: 10.1158/1078-0432.CCR-11-0445
Bissler, J. J. et al. Everolimus long-term use in patients with tuberous sclerosis complex: four-year update of the EXIST-2 study. PLoS One 12, e0180939 (2017).
pmcid: 5549893
doi: 10.1371/journal.pone.0180939
Bissler, J. J. et al. Everolimus for renal angiomyolipoma associated with tuberous sclerosis complex (TSC) from EXIST-2: continued efficacy and diminishing adverse events after ~3.5 years of treatment. Eur. Urol. Suppl. 14, e1 (2015).
doi: 10.1016/S1569-9056(15)60004-5
Budde, K. et al. Predictive value of angiogenic biomarkers in tuberous sclerosis complex (TSC) patients with renal angiomyolipoma (AML). Eur. Urol. Suppl. 12, e981–e982 (2013).
doi: 10.1016/S1569-9056(13)61459-1
Bissler, J. J. et al. Angiomyolipoma rebound tumor growth after discontinuation of everolimus in patients with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis. PLoS One 13, e0201005 (2018).
pmcid: 6128468
doi: 10.1371/journal.pone.0201005
Waksman, R. et al. Oral rapamycin inhibits growth of atherosclerotic plaque in apoE knock-out mice. Cardiovasc. Radiat. Med. 4, 34–38 (2003).
doi: 10.1016/S1522-1865(03)00121-5
Pakala, R., Stabile, E., Jang, G. J., Clavijo, L. & Waksman, R. Rapamycin attenuates atherosclerotic plaque progression in apolipoprotein E knockout mice: inhibitory effect on monocyte chemotaxis. J. Cardiovasc. Pharmacol. 46, 481–486 (2005).
doi: 10.1097/01.fjc.0000177985.14305.15
Franz, D. N. et al. Long-term use of everolimus in patients with tuberous sclerosis complex: final results from the EXIST-1 study. PLoS One 11, e0158476 (2016).
pmcid: 4924870
doi: 10.1371/journal.pone.0158476
Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int. 105, S1–S197 (2024).
doi: 10.1016/j.kint.2023.09.002
Somers, M. J. & Paul, E. Safety considerations of mammalian target of rapamycin inhibitors in tuberous sclerosis complex and renal transplantation. J. Clin. Pharmacol. 55, 368–376 (2015).
doi: 10.1002/jcph.428
Franz, D. N. et al. Effect of everolimus on skin lesions in patients treated for subependymal giant cell astrocytoma and renal angiomyolipoma: final 4-year results from the randomized EXIST-1 and EXIST-2 studies. J. Eur. Acad. Dermatol. Venereol. 32, 1796–1803 (2018).
doi: 10.1111/jdv.14964
Fernández-Pello, S. et al. Management of sporadic renal angiomyolipomas: a systematic review of available evidence to guide recommendations from the European Association of Urology renal cell carcinoma guidelines panel. Eur. Urol. Oncol. 3, 57–72 (2020).
doi: 10.1016/j.euo.2019.04.005
Lenton, J., Kessel, D. & Watkinson, A. F. Embolization of renal angiomyolipoma: immediate complications and long-term outcomes. Clin. Radiol. 63, 864–870 (2008).
doi: 10.1016/j.crad.2008.02.005
Danforth, T. L., Lane, B. R. & Novick, A. C. Conservative management of giant symptomatic angiomyolipomas in patients with the tuberous sclerosis complex. BJU Int. 100, 794–797 (2007).
doi: 10.1111/j.1464-410X.2007.07059.x
Storm, D. W. & Mowad, J. J. Conservative management of a bleeding renal angiomyolipoma in pregnancy. Obstet. Gynecol. 107, 490–492 (2006).
doi: 10.1097/01.AOG.0000167392.59472.c3
Chan Park, M. et al. Varying outcomes among patients with large angiomyolipomas according to the treatment method. Urol. Int. 105, 680–686 (2021).
doi: 10.1159/000515990
Andrassy, K. M. Comments on ‘KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int. 84, 622–623 (2013).
doi: 10.1038/ki.2013.243
Kutikov, A. & Uzzo, R. G. The R.E.N.A.L. nephrometry score: a comprehensive standardized system for quantitating renal tumor size, location and depth. J. Urol. 182, 844–853 (2009).
doi: 10.1016/j.juro.2009.05.035
Bissler, J. J., Racadio, J., Donnelly, L. F. & Johnson, N. D. Reduction of postembolization syndrome after ablation of renal angiomyolipoma. Am. J. Kidney Dis. 39, 966–971 (2002).
doi: 10.1053/ajkd.2002.32770
Tsuchiya, S. et al. Prophylactic steroids for preventing postembolization syndrome after transcatheter arterial embolization of renal angiomyolipoma: a comparative study. Interv. Radiol. 8, 1–6 (2023).
doi: 10.22575/interventionalradiology.2021-0015
Minervini, A. et al. Simple enucleation for the treatment of renal angiomyolipoma. BJU Int. 99, 887–891 (2007).
doi: 10.1111/j.1464-410X.2006.06702.x
Yip, S. K., Tan, P. H., Cheng, W. S., Li, M. K. & Foo, K. T. Surgical management of angiomyolipoma: nephron-sparing surgery for symptomatic tumour. Scand. J. Urol. Nephrol. 34, 32–35 (2000).
doi: 10.1080/003655900750016850
Whiting, D. et al. Complications after radical nephrectomy according to age: analysis from the British Association of Urological Surgeons nephrectomy audit. J. Endourol. 36, 188–196 (2022).
doi: 10.1089/end.2021.0165
Sooriakumaran, P. et al. Angiomyolipomata: challenges, solutions, and future prospects based on over 100 cases treated. BJU Int. 105, 101–106 (2010).
doi: 10.1111/j.1464-410X.2009.08649.x
Voss, M. H. et al. PTEN expression, not mutation status in TSC1, TSC2, or mTOR, correlates with the outcome on everolimus in patients with renal cell carcinoma treated on the randomized RECORD-3 trial. Clin. Cancer Res. 25, 506–514 (2019).
doi: 10.1158/1078-0432.CCR-18-1833
Nassar, A. H. et al. Mutations and response to rapalogs in patients with metastatic renal cell carcinoma. Mol. Cancer Ther. 19, 690–696 (2020).
doi: 10.1158/1535-7163.MCT-19-0642
Kwiatkowski, D. J. et al. Mutations in TSC1, TSC2, and MTOR are associated with response to rapalogs in patients with metastatic renal cell carcinoma. Clin. Cancer Res. 22, 2445–2452 (2016).
pmcid: 4976069
doi: 10.1158/1078-0432.CCR-15-2631
Roldan-Romero, J. M. et al. PTEN expression and mutations in TSC1, TSC2 and MTOR are associated with response to rapalogs in patients with renal cell carcinoma. Int. J. Cancer 146, 1435–1444 (2020).
doi: 10.1002/ijc.32579
Bjornsson, J., Short, M. P., Kwiatkowski, D. J. & Henske, E. P. Tuberous sclerosis-associated renal cell carcinoma. Clinical, pathological, and genetic features. Am. J. Pathol. 149, 1201–1208 (1996).
pmcid: 1865172
Auvin, S. et al. A step-wise approach for establishing a multidisciplinary team for the management of tuberous sclerosis complex: a Delphi consensus report. Orphanet J. Rare Dis. 14, 91 (2019).
pmcid: 6492321
doi: 10.1186/s13023-019-1072-y
Fujimoto, A. et al. Establishment of a regional interdisciplinary medical system for managing patients with tuberous sclerosis complex (TSC). Sci. Rep. 8, 16747 (2018).
pmcid: 6233214
doi: 10.1038/s41598-018-35168-y
Thiele, E. A., Granata, T., Matricardi, S. & Chugani, H. T. Transition into adulthood: tuberous sclerosis complex, Sturge-Weber syndrome, and Rasmussen encephalitis. Epilepsia 55, 29–33 (2014).
doi: 10.1111/epi.12722
McGarry, L., Messer, R., Cree-Green, M., Ray, K. & Knupp, K. Incidence of hypertension among children treated with adrenocorticotropic hormone (ACTH) or prednisolone for infantile spasms. J. Child Neurol. 35, 215–220 (2020).
doi: 10.1177/0883073819886244